{"schema_version":"1.0","type":"article","title":"這一批罕見病患者終於等來新藥！","url":"https://drugnews.com.tw/articles/2026-04-09-dcard-261263509.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-09-dcard-261263509.md","lang":"zh-Hant","date":"2026-04-09","publish_at":"2026-04-09T10:30:00+08:00","updated_at":"2026-04-09","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","AI","臨床數據","生技投資"],"summary":"美國 FDA 近日加速核准 Denali Therapeutics 的 AVLAYAH（tividenofusp alfa-eknm），用於治療 Hunter syndrome （韓特氏症），也就是 mucopolysaccharidosis type II（MPS II） 的神經學表現。","key_points":[],"facts":[],"sections":["近 20 年來，美國終於等到一個能碰到腦部病程的 Hunter syndrome 新藥","為什麼 Hunter syndrome 這麼難治，核心從來不是酵素替代本身不成立","AVLAYAH 真正的突破，不只是一支新酵素，而是一種新的遞送設計","這次核准，也等於替整個 BBB-penetrant biologics 類別開了一條路","對患者來說，這次核准真正帶來的是「病程想像」的改變"],"references":[{"title":"[0]:各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome","source":"FDA","date":"","url":""},{"title":"The U.S. Food and Drug Administration approved Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"\"FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome","source":"FDA\"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Close banner","source":"","date":"","url":""},{"title":"https://www.nature.com/articles/s41587-026-03066-8","source":"","date":"","url":"https://www.nature.com/articles/s41587-026-03066-8"},{"title":"www.nature.com","source":"","date":"","url":""},{"title":"\"BBB Hunter agent nears FDA decision","source":"Nature Biotechnology\"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"JCR Pharmaceuticals Announces Approval of IZCARGO® (Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japan - Neuro Central","source":"","date":"","url":""},{"title":"– First Approved Enzyme Replacement Therapy for MPS II to Penetrate Blood-Brain Barrier via Intravenous Administration, Validating JCR’s J-Brain Cargo® Technology – HYOGO, Japan–(BUSINESS WIRE)–JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) today announc","source":"","date":"","url":""},{"title":"www.neuro-central.com","source":"","date":"","url":""},{"title":"\"JCR Pharmaceuticals Announces Approval of IZCARGO® (Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japan - Neuro Central\"","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"\"Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II","source":"Denali Therapeutics\"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"\"REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II","source":"Regenxbio Inc\"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome","source":"","date":"","url":""},{"title":"Idursulfase beta (Hunterase®) has been used for enzyme replacement therapy (ERT) of patients with mucopolysaccharidosis II (MPS II, Hunter syndrome) aged 6 years or older since 2012 in Korea. The objective of this study was to evaluate the safety and effi","source":"","date":"","url":""},{"title":"pubmed.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"\"Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome - PubMed\"","source":"","date":"","url":""},{"title":"[7]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-denalis-genetic-disorder-therapy-2026-03-25/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-denalis-genetic-disorder-therapy-2026-03-25/"},{"title":"www.reuters.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：這一批罕見病患者終於等來新藥！（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261263509/dcard-01.webp"},{"alt":"Dcard 原圖：這一批罕見病患者終於等來新藥！（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261263509/dcard-02.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261263509/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-09）。這一批罕見病患者終於等來新藥！。https://drugnews.com.tw/articles/2026-04-09-dcard-261263509.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-09-dcard-261263509-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}